A decision on whether to open a costly cancer drug to generic competition will be made shortly. It doesn’t require congressional approval.
Medicare
Posted inHealth and Social Policy
The Dark History of Medicare Privatization
Medicare Advantage was supposed to be a money-saver. It’s now become a costly, unaccountable cash cow for private insurance companies that is swallowing traditional Medicare.
Posted inHealth and Social Policy
Biden Regulators Take Action on Hidden Pharma Monopolies
A proposed rule would eliminate the ability of pharmacy benefit managers to extract profits after a prescription drug is sold.
Posted inPolitics
Toxic Ads and How to Counter Them
Anticipating and rebutting likely lines of attack is the best strategy, on both partisan and civic grounds.
Posted inBuilding Back America
The Drug Price/Tax Break Quid Pro Quo
Democrats in high-tax states cut a deal on the Build Back Better Act.
Posted inTAP
World’s Biggest Half-Full, Half-Empty Glass
Today on TAP: Biden’s bill is historically great and bitterly disappointing.
Posted inBuilding Back America
What’s in the Build Back Better Framework
It has its selling points. But it doesn’t appear to meet the test of permanent, hassle-free, and meaningful.
Posted inMoney, Politics, and Power
The Drug Industry–Backed PAC Trying to Spike the Biden Agenda
Center Forward is funding practically all the corporate Democrats making trouble in Congress.
Posted inHealth and Social Policy
Lowering Drug Prices Is Personal for Millions of Americans
Lost in the technical debate over drug prices is a struggle to afford medications happening across the country.
Posted inHealth and Social Policy
Democrats Expand Obamacare While Abandoning It
While learning the lessons of the Affordable Care Act, Democrats are still building on top of it instead of seeking a better design.
